A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer - ...

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

The American Medical Association and more than two dozen other health organizations joined in an amicus brief encouraging the ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

Andri Papakonstantinou has been awarded the Pfizer and Swedish Society of Oncology's (SOF) research scholarship in oncology ...

Accelerated aging in breast cancer survivors is linked to treatments and tumor characteristics, with implications for ...

Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the ...